UK markets closed

Vistin Pharma ASA (0RAM.L)

LSE - LSE Delayed price. Currency in NOK
Add to watchlist
24.30+0.40 (+1.67%)
At close: 09:05AM BST
Full screen
Previous close23.90
Open0.00
Bid0.00 x N/A
Ask0.00 x N/A
Day's range0.00 - 0.00
52-week range
Volume280
Avg. volume886
Market capN/A
Beta (5Y monthly)0.89
PE ratio (TTM)0.43
EPS (TTM)0.56
Earnings date23 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Vistin Pharma ASA: Minutes from the annual general meeting 2024

    Oslo, Norway, 23 May 2024 Vistin Pharma ASA (OSE: VISTN), please find attached the minutes from the annual general meeting held today, on the 23 May 2024. All matters were resolved as proposed in the call for the annual general meeting, including the proposal to distribute a dividend of total NOK 1 per share, to be paid partly in June (NOK 0.5) and November (NOK 0.5). For the June dividend of NOK 0.5 per share, the shares will be traded excluding the right (ex-date) on the 5th of June, with paym

  • Globe Newswire

    Vistin Pharma ASA: Notice of Annual General Meeting 23 May 2024

    Oslo, Norway, 30 April 2024 Vistin Pharma ASA (OSE: VISTN), please find attached the call for the Annual General Meeting in Vistin Pharma, to be held on 23 May 2024 at 13:00 CEST. A physical Annual General Meeting will not be held. Instead, shareholders should authorize the Chairman of the Board. It is possible to give proxy with and without voting instructions. By using a proxy with voting instructions, the shareholders will vote on the specific issues without personal attendance. For further i

  • Globe Newswire

    Vistin Pharma ASA: First quarter 2024 financial results

    Oslo, Norway, 24th of April 2024 Vistin Pharma ASA (VISTN) today announces the financial results for the first quarter of 2024. Revenue in the first quarter ended at MNOK 104 compared to MNOK 101 in Q1 2023. Sales volume in the quarter was up by 11% compared to Q1 2023. First quarter EBITDA ended at MNOK 20 compared to MNOK 14 in Q1 2023, representing a 45% increase. EBITDA positively affected by increased sales volume and product mix, partly offset by a one-time inventory adjustment of MNOK 7.